Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its proprietary drug, Xinkang Capsules, aimed at treating cancer-related fatigue [1] Company Summary - Xinkang Capsules are an exclusive proprietary medicine developed by the company, presented in a capsule form with a specification of 0.45g per capsule [1] - The drug is a result of the company's independent research and development efforts in traditional Chinese medicine [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for cancer-related fatigue, which may enhance the company's position in the pharmaceutical market [1]

Core Viewpoint - Xintian Pharmaceutical (002873.SZ) has received approval from the National Medical Products Administration for clinical trials of Xinkang Capsules, aimed at treating cancer-related fatigue in colon cancer patients [1] Group 1: Company Developments - The approval allows Xintian Pharmaceutical to conduct clinical trials to validate the efficacy of Xinkang Capsules for treating cancer-related fatigue (CRF) [1] - Cancer-related fatigue is defined as a painful, persistent sense of exhaustion that cannot be alleviated by rest, often accompanied by cognitive impairment and emotional distress [1] Group 2: Industry Context - The clinical practice guidelines for cancer-related fatigue in China (2021 edition) outline the characteristics and impact of CRF on patients' daily lives [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of Xinlikang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The approval allows the company to conduct clinical trials for Xinlikang capsules [1] - The indication for the clinical trial is specifically for the treatment of cancer-related fatigue [1]

Group 1 - The core point of the article is that Xintian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xinlikang capsules, aimed at treating cancer-related fatigue [1] - As of October 14, Xintian Pharmaceutical's market capitalization is 2.6 billion yuan [2] - For the first half of 2025, Xintian Pharmaceutical's revenue composition shows that main business revenue accounts for 99.9%, while other business revenue accounts for 0.1% [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The company has announced the receipt of a clinical trial approval notice for Xin Likang capsules [1] - The clinical trial is specifically for the treatment of cancer-related fatigue [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The approval allows the company to conduct clinical trials for Xin Likang capsules [1] - The indication for the clinical trial is specifically for the treatment of cancer-related fatigue [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for its Xin Likang capsules, aimed at treating cancer-related fatigue, marking a significant step in addressing an unmet medical need in this area [1] Company Summary - Xin Tian Pharmaceutical announced the receipt of a clinical trial approval notice for Xin Likang capsules, which are a unique Miao medicine [1] - The clinical trials will focus on validating the efficacy of Xin Likang capsules in treating cancer-related fatigue specifically in colon cancer patients [1] - Currently, there are no drugs available in the domestic or international markets for the treatment of cancer-related fatigue [1] Industry Summary - The approval for clinical trials highlights a potential breakthrough in the pharmaceutical industry, particularly in the niche of cancer-related fatigue treatment [1] - The development of Xin Likang capsules could fill a significant gap in the market, as there are no existing therapies for this condition [1] - The progress and results of the clinical trials remain uncertain, and the company will fulfill its information disclosure obligations as required [1]

证券代码：002873 证券简称：新天药业 公告编号：2025-055 贵阳新天药业股份有限公司 关于获得欣力康胶囊《药物临床试验批准通知书》的 公告 剂型：胶囊剂 申请事项：临床试验 受理号：CXZL2500054 通知书编号：2025LP02676 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年7月24日受理的欣力康胶囊（CXZL2500054）临床试验申请符合药品注册的有 关要求，在进一步完善临床试验方案的基础上，同意本品开展用于癌因性疲乏的 临床试验。 二、药品研发及相关情况 欣力康胶囊为公司的独家苗药品种，胶囊制剂，规格0.45g/粒。是公司自主 研发的中药。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）于近日收到了国家药品监 督管理局下发的欣力康胶囊《药品临床试验批准通知书》，同意欣力康胶囊开展 "用于癌因性疲乏的治疗"的临床试验，现将相关情况公告如下： 一、药物临床试验批准通知书的主要内容 产品名称：欣力康胶囊 产品功能主治：苗医：布苯怡象，维象样丢象，泱窇沓痂；中医：补 ...

（编辑 袁冠琳） 证券日报网讯 新天药业9月30日在互动平台回答投资者提问时表示，公司已于2024年7月26日披露了终 止发行股份购买资产事项的公告，具体内容详见公司已发布的相关公告。但打造行业领先的综合性医药 企业仍是公司的长期发展战略。 ...

证券日报网讯新天药业（002873）9月29日在互动平台回答投资者提问时表示，公司持续增加对汇伦医 药的投资是基于公司中长期发展规划目标所做出的审慎决策。汇伦医药作为一家聚焦于重大疾病和危重 症治疗领域的创新型医药企业，具备较强的小分子化药创新研发能力。通过增加对汇伦医药的投资，加 大公司在小分子化药领域的投入，有利于进一步提升公司未来的市场竞争力，加速打造公司实现行业领 先的综合性医药企业战略目标。 ...